New publication - Attana’s technology was used to develop a specific antibody fragment for treatment of inflammatory diseases
A new paper has been published in mAbs by Dr. Richter and co-workers at University of Stuttgart. The aim of the study was to develop a novel, monovalent antibody inhibitor of inflammatory activation with extended serum half-life. Attana's QCM technology was used to optimize the specific interaction properties of the inhibitor.Tumor necrosis factor (TNF) plays a central role in the immune system, especially during inflammation and infection. Dysregulated expression of TNF is associated with severe inflammatory conditions